Intramuscular extended‐release naltrexone: current evidence

摘要: Extended-release naltrexone (XR-NTX; Vivitrol), developed to address poor adherence in addictive disorders, is approved for use alcohol and opioid-dependence disorders. In alcohol-dependent adults with ≥ 4-day initial abstinence, XR-NTX increased 6-month abstinence. An fMRI study found that attenuated the salience of visual olfactory cues absence alcohol, post hoc analyses demonstrated efficacy even during high cue-exposure holiday periods. Safety tolerability have generally been good, without adverse hepatic impact or intractable acute pain management. appears feasible primary care public systems, retrospective claims cost savings decreased intensive service utilization relative oral agents. opioid dependence, following detoxification, shows maintaining improving retention, decreasing craving, preventing relapse. Trials are also exploring its treatment stimulant dependence. compatible counseling self-help attendance. While more research needed, current findings suggest a formulation was sought beginning over three decades ago fulfilling promise as an extended-release pharmacotherapeutic.